BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25187155)

  • 1. The impact of exposure model misspecification on signal detection in prospective pharmacovigilance.
    van Gaalen RD; Abrahamowicz M; Buckeridge DL
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):456-67. PubMed ID: 25187155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.
    van Gaalen RD; Abrahamowicz M; Buckeridge DL
    Drug Saf; 2017 Nov; 40(11):1119-1129. PubMed ID: 28664355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A conceptual approach to the masking effect of measures of disproportionality.
    Maignen F; Hauben M; Hung E; Holle LV; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):208-17. PubMed ID: 24243699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structured assessment for prospective identification of safety signals in electronic medical records: evaluation in the health improvement network.
    Cederholm S; Hill G; Asiimwe A; Bate A; Bhayat F; Persson Brobert G; Bergvall T; Ansell D; Star K; Norén GN
    Drug Saf; 2015 Jan; 38(1):87-100. PubMed ID: 25539877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal detection for Thai traditional medicine: examination of national pharmacovigilance data using reporting odds ratio and reported population attributable risk.
    Wechwithan S; Suwankesawong W; Sornsrivichai V; McNeil EB; Jiraphongsa C; Chongsuvivatwong V
    Regul Toxicol Pharmacol; 2014 Oct; 70(1):407-12. PubMed ID: 24945744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.
    Lai EC; Pratt N; Hsieh CY; Lin SJ; Pottegård A; Roughead EE; Kao Yang YH; Hallas J
    Eur J Epidemiol; 2017 Jul; 32(7):567-582. PubMed ID: 28698923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoepidemiology and its input to pharmacovigilance.
    Faillie JL; Montastruc F; Montastruc JL; Pariente A
    Therapie; 2016 Apr; 71(2):211-6. PubMed ID: 27080840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases.
    Leroy F; Dauxois JY; Théophile H; Haramburu F; Tubert-Bitter P
    BMC Med Res Methodol; 2014 Feb; 14():17. PubMed ID: 24490673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
    Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
    Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance.
    Hauser AS; Kooistra AJ; Sverrisdóttir E; Sessa M
    Expert Opin Drug Saf; 2020 Aug; 19(8):961-968. PubMed ID: 32510245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
    Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches.
    De Abreu Ferreira R; Zhong S; Moureaud C; Le MT; Rothstein A; Li X; Wang L; Patwardhan M
    Adv Ther; 2024 Jun; 41(6):2435-2445. PubMed ID: 38704799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital.
    Khan LM; Al-Harthi SE; Saadah OI; Al-Amoudi AB; Sulaiman MI; Ibrahim IM
    Saudi Med J; 2012 Aug; 33(8):863-8. PubMed ID: 22886119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application and optimisation of the Comparison on Extreme Laboratory Tests (CERT) algorithm for detection of adverse drug reactions: Transferability across national boundaries.
    Tham MY; Ye Q; Ang PS; Fan LY; Yoon D; Park RW; Ling ZJ; Yip JW; Tai BC; Evans SJ; Sung C
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):87-94. PubMed ID: 29108136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
    Pratt N; Chan EW; Choi NK; Kimura M; Kimura T; Kubota K; Lai EC; Man KK; Ooba N; Park BJ; Sato T; Shin JY; Wong IC; Kao Yang YH; Roughead EE
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):858-64. PubMed ID: 25907076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.